OptimizeRx integrates its EHR network with DeepIntent, enhancing healthcare advertising within HCP workflows.
Quiver AI Summary
OptimizeRx Corp. has announced a collaboration with DeepIntent, a leading healthcare demand-side platform, to integrate OptimizeRx’s electronic health record (EHR) network into DeepIntent's advertising platform. This collaboration aims to simplify the activation of advertising within healthcare provider workflows, leveraging OptimizeRx's validated EHR inventory alongside DeepIntent's programmatic capabilities. The partnership addresses the increasing demand for privacy-safe advertising linked to clinical workflows, allowing life sciences marketers to reach healthcare providers at critical decision-making moments. The EHR network will be available on the DeepIntent platform by Q3 2026, enhancing marketers' ability to execute scalable, targeted campaigns while improving engagement with providers and patient outcomes.
Potential Positives
- OptimizeRx's collaboration with DeepIntent positions it as a leader in integrating electronic health record (EHR) technology into digital advertising, enhancing its market presence.
- The integration into DeepIntent's platform facilitates easier access to OptimizeRx's EHR inventory, potentially driving increased revenue through programmatic advertising solutions for life sciences marketers.
- This partnership addresses the rising demand for privacy-safe advertising solutions, aligning with contemporary healthcare marketing needs and trends.
- OptimizeRx aims to expand programmatic access to its EHR network, which may lead to broader market opportunities and increased engagement in point of care environments.
Potential Negatives
- The press release contains numerous forward-looking statements, indicating a reliance on projections that may not materialize, which introduces uncertainty about the company's future performance.
- There is a potential risk associated with dependence on a concentrated group of customers, which could impact financial stability if those relationships deteriorate.
- The company warns of competition and the need to keep pace with evolving technology, suggesting that they face significant challenges in maintaining their market position.
FAQ
What is the OptimizeRx and DeepIntent collaboration about?
The collaboration integrates OptimizeRx’s EHR network into DeepIntent’s DSP for healthcare advertising, enhancing provider engagement.
When will OptimizeRx’s EHR network be available on DeepIntent?
OptimizeRx’s EHR network is expected to be available on DeepIntent's platform in Q3 2026.
How does this integration benefit life sciences marketers?
This integration allows marketers to activate EHR inventory directly within a trusted platform, improving the efficiency of healthcare advertising.
What are the advantages of using programmatic buying in healthcare?
Programmatic buying allows scalable, timely campaigns directly within clinical workflows, enhancing provider engagement and decision-making.
Why is privacy-safe advertising important in healthcare?
Privacy-safe advertising protects patient information while enabling marketers to reach providers with relevant, clinical information at critical moments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPRX Insider Trading Activity
$OPRX insiders have traded $OPRX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $OPRX stock by insiders over the last 6 months:
- EDWARD STELMAKH (Chief Finance & Strat Officer) sold 1,388 shares for an estimated $18,751
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OPRX Revenue
$OPRX had revenues of $19.8M in Q1 2026. This is a decrease of -9.5% from the same period in the prior year.
You can track OPRX financials on Quiver Quantitative's OPRX stock page.
You can access data on OPRX stock through the Quiver Quantitative API.
$OPRX Hedge Fund Activity
We have seen 71 institutional investors add shares of $OPRX stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NEXT CENTURY GROWTH INVESTORS LLC removed 505,407 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,173,955
- MANATUCK HILL PARTNERS, LLC removed 372,107 shares (-88.2%) from their portfolio in Q1 2026, for an estimated $2,336,831
- G2 INVESTMENT PARTNERS MANAGEMENT LLC removed 310,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,946,800
- GOLDMAN SACHS GROUP INC added 231,429 shares (+182.2%) to their portfolio in Q1 2026, for an estimated $1,453,374
- INVENOMIC CAPITAL MANAGEMENT LP added 229,370 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,440,443
- D. E. SHAW & CO., INC. removed 208,184 shares (-64.8%) from their portfolio in Q4 2025, for an estimated $2,552,335
- AQR CAPITAL MANAGEMENT LLC added 200,440 shares (+1381.0%) to their portfolio in Q1 2026, for an estimated $1,258,763
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$OPRX Analyst Ratings
Wall Street analysts have issued reports on $OPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 05/13/2026
To track analyst ratings and price targets for $OPRX, check out Quiver Quantitative's $OPRX forecast page.
$OPRX Price Targets
Multiple analysts have issued price targets for $OPRX recently. We have seen 5 analysts offer price targets for $OPRX in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- David Grossman from Stifel set a target price of $14.0 on 05/13/2026
- Jeff Garro from Stephens & Co. set a target price of $7.0 on 05/13/2026
- Anderson Schock from B. Riley Securities set a target price of $10.0 on 05/13/2026
- Eric Martinuzzi from Lake Street set a target price of $11.0 on 05/13/2026
- Richard Baldry from Roth Capital set a target price of $18.0 on 03/06/2026
Full Release
WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced that DeepIntent , the leading healthcare demand-side platform (DSP), will be the first DSP to integrate OptimizeRx’s proprietary electronic health record (EHR) network into its healthcare advertising platform.
By combining OptimizeRx’s authenticated EHR network with DeepIntent’s healthcare-first DSP capabilities, this collaboration gives life sciences marketers an easier way to activate advertising within HCP workflows, using the same programmatic tools they already rely on for digital media buying. This collaboration also reflects the growing demand for privacy-safe advertising solutions tied to real clinical workflows.
“Our integration with DeepIntent makes validated EHR inventory easier to activate within a platform our clients already trust and value,” said Steve Silvestro, Chief Executive Officer at OptimizeRx. “As we expand programmatic access to our authenticated EHR network, our focus is helping more brands deliver measurable point of care engagement.”
Bringing Programmatic Buying into the Clinical Workflow
As healthcare marketers navigate growing signal loss, tighter privacy standards, and other limitations across traditional open-web advertising, demand is growing for more deterministic, measurable ways to reach providers at clinically relevant moments.
Building on DeepIntent’s existing point of care and omnichannel capabilities, the OptimizeRx integration enables life science marketers to:
- Access OptimizeRx’s authenticated EHR inventory directly within DeepIntent’s platform
- Extend omnichannel campaigns into point of care environments
- Reach providers closer to clinical decision moments
-
Activate scalable point of care campaigns with the speed, control, and flexibility of programmatic buying
DeepIntent is widely recognized for its healthcare-focused DSP capabilities, including audience targeting, activation, optimization, and measurement solutions designed specifically for life sciences brands. Adding reach within OptimizeRx’s proprietary EHR network helps marketers better align media activation with provider engagement across the care journey.
“We’re excited to bring OptimizeRx’s industry-leading EHR network to our established client base of pharmaceutical brands, healthcare agencies, and enterprise marketers,” said Lisa Kopp Johnson, Chief Revenue Officer, DeepIntent. “By offering scalable access to providers directly within their clinical workflows, we can help deliver more timely and relevant information that supports informed care decisions and better patient outcomes. This partnership comes as DeepIntent is building the richest marketplace of vital inventory relevant to our clients.”
Expanding Access to Point of Care Media
The DeepIntent collaboration reflects OptimizeRx’s broader strategy to expand programmatic access to its authenticated EHR network through select DSP partnerships. By opening its infrastructure to additional demand-side integrations over time, the company aims to make clinically aligned point of care media more accessible within modern healthcare advertising workflows.
Availability
OptimizeRx’s authenticated EHR network is expected to be available on the DeepIntent platform in Q3 2026. For more information about availability or to inquire about DSP integration opportunities, please contact us at https://www.optimizerx.com/contact-us .
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life sciences brands connect with patients and healthcare providers. Our platform combines innovative, AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood ® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on LinkedIn or X , or visit www.optimizerx.com .
About DeepIntent
DeepIntent is the leading healthcare demand-side platform (DSP), purpose-built to help marketers plan, activate, and optimize data-driven campaigns with speed and precision. Trusted by the world’s top healthcare brands and their agencies, DeepIntent uniquely unites media, identity, and real-world clinical data to power privacy-safe, omnichannel marketing across every screen. Backed by patented technology and proven outcomes, DeepIntent’s platform delivers measurable audience quality and script lift at scale. Learn more at www.deepintent.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "will", "can", "activate", “access”, “expanding", "incorporate", "connecting" or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company's expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the availability of OptimizeRx’s EHR inventory on the DeepIntent DSP, the growing demand for privacy-safe advertising solutions tied to real clinical workflows, the success of pharmaceutical brands to deliver measurable point of care management, the ability of healthcare marketers to activate point of care campaigns at scale, expansion of programmatic access to the Company’s EHR network, and the accessibility of clinically aligned point of care media within healthcare advertising workflows. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company's business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Jennifer Dinkel, VP Marketing
[email protected]
OptimizeRx Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
[email protected]
OptimizeRx Press Inquiries
Matter Communications
[email protected]
DeepIntent Press Inquiries
[email protected]
OptimizeRx Partnership Inquiries
Louis Trivento, SVP Strategic Partnerships
[email protected]